Vasopressor support in managing acute spinal cord injury: current knowledge

Area of Science:

• Neuroscience
• Critical Care Medicine
• Pharmacology

Background:

• Neurogenic shock following acute traumatic spinal cord injury (SCI) presents significant management challenges.
• Current guidelines recommend maintaining mean arterial pressure (MAP) above 85-90 mmHg to ensure spinal cord perfusion.
• Early vasopressor use shows promise, but specific agent indications require further clarification.

Purpose of the Study:

• To review current evidence on vasopressor use in neurogenic shock post-acute SCI.
• To compare the efficacy and complications of different vasopressors.
• To identify gaps in knowledge for refining clinical guidelines.

Main Methods:

• A systematic literature search was performed on the PubMed database (2010-2017).
• Studies focused on adult patients with acute SCI experiencing neurogenic shock or hypotension.
• Endpoints included comparative advantages, complications, and adjunctive therapies.

Main Results:

• Seven studies met the inclusion criteria.
• Dopamine was associated with higher complication rates than phenylephrine in SCI patients.
• Norepinephrine showed a modest increase in spinal cord perfusion pressure without significant MAP differences compared to dopamine.
• Elderly SCI patients experienced more vasopressor-related complications.
• Oral pseudoephedrine was noted as a potential adjunct for weaning intravenous vasopressors.
• No correlation was found between MAP thresholds (65-90 mmHg) and neurological outcomes.

Conclusions:

• Existing evidence on vasopressor use in acute SCI is limited (Class III).
• Comparative benefits of specific vasopressors require further investigation due to small sample sizes and lack of specificity.
• Large prospective studies are needed to establish judicious use criteria for vasopressors in diverse SCI subpopulations.